Navigation Links
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
Date:4/19/2012

ot available due to treatment duration  

Investigators reported breakthrough broken out by genotype and IL-28B status. In GT1b and GT1a-CC patients, breakthrough occurred in 7 percent of patients in Arm A, 11 percent of patients in Arm B, 19 percent of patients in Arm C, 9 percent of patients in Arm D, and 29 percent of patients in Arm E (no RBV arm). In GT1a non-CC patients, breakthrough occurred in 40 percent of patients in Arm A, 50 percent of patients in Arm B, 25 percent of patients in Arm C, 64 percent of patients in Arm D, and 91 percent of patients in Arm E (no RBV arm).

In this study, the most common adverse events (AEs) were skin (photosensitivity, rash), gastrointestinal (GI) disorders (vomiting, diarrhea), and jaundice due to unconjugated hyperbilirubinemia. Treatment discontinuations due to AEs correlated with increased dosing frequency and treatment duration, with discontinuations ranging from 4.9 percent in Arm A (16 weeks) to 24.7 percent in Arm C (40 weeks). In the arm with BID dosing of BI 207127 (Arm D), discontinuations were 7.7 percent. BID dosing of BI 207127 is planned for Phase 3 investigation.

Other BI data being presented at the EASL Annual Meeting include: Poster PresentationsTitleLead Author Presentation Details SOUND-C2 interim analysis:
The efficacy and safety of the
interferon-free combination of
BI 201335 and BI 207127 in
genotype-1 HCV patients with
cirrhosis

V. Soriano

Late Breaker Poster# 1420

 

Date: Thur, April 19

Time: 12:00 - 1:30 p.m.
CEST/ 6:00 - 7:30 a.m. EDT

 Characterization of HCV NS3
variants that emerged during
virologic breakthrough and
relapse from BI 201335 Phase
2 SILEN-C2 study in
pegylated-interferon plus
ribavirin treatment-
experienced patients

G. Kukolj

Poster# 1185

 

Date: Sat, April 21

Time: 12:30 – 1:30 p.m.
CEST/ 6:30 &
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
2. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
3. Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
4. QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
5. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
6. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
7. Bionovos Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
8. Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
9. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
10. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
11. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Zacks.com announces the list ... Zacks Equity Research analysts discuss the latest news and events ... the blog include the Hewlett-Packard (NYSE: HPQ - Free Report ... Bulkers, Inc. (NYSE: SB - Free Report ), GlaxoSmithKline ... International N.V. (NYSE: FI - Free Report ). ...
(Date:8/21/2014)... 21, 2014 InfinityQS International, Inc., the ... Intelligence , today announces Infusion Chicago, its 9 ... be held Oct. 9-10, 2014, at the Chicago ... showcase the necessity for implementing a quality system ... Intelligence to gain insight into production processes. Complimentary ...
(Date:8/21/2014)... , Aug. 21, 2014  The board of directors ... leading provider of clinical trial imaging solutions, today announced ... chief financial officer, effective immediately.  Mr. Groff has held ... 2013.  He joined VirtualScopics in January 2006 as an ... 2013. "When the board of VirtualScopics asked ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... FRANCISCO, June 22, 2011 Autonomy Corporation plc ... infrastructure software for the enterprise, today announced that the ... Autonomy,s flagship Web Content Management (WCM) platform, has twice ... Site Monitor performance report. The Swiss Pharma Site Monitor ...
... FALL RIVER, Mass., June 21, 2011 Millstone ... introduced an advanced version of its online inventory ... refinement, Millstone launched a new online, password-protected system ... place orders, and manage distribution.  Benefits of the ...
Cached Medicine Technology:Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 2Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 3Autonomy Powers Award-Winning Website for Leading Swiss Pharmaceutical Company 4Millstone Medical Outsourcing Introduces Advanced Version of Online Inventory Management System 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 According ... Type & Application - Global Trends & Forecast ... with an analysis and forecast of the market ... to $38,729 million by 2019, at a significant ... market data tables and 44 figures spread through ...
(Date:8/22/2014)... Hallandale Beach, Florida (PRWEB) August 22, 2014 ... treatment for Lasik in Fort Lauderdale at the most ... patients get better eyesight through their advanced Lasik treatments. ... available worldwide and the Braverman Eye Center has been ... thousands of patients live a glasses-free and contact lenses-free ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across the ... with Crohn,s disease (CD), reports Inflammatory Bowel Diseases ... Foundation of America (CCFA). The journal is published ... Wolters Kluwer Health . , The study ... of the genome in children with CD, according to Professor ...
(Date:8/22/2014)... confused with lactose intolerance. However, these are two entirely ... lactose intolerance do not digest lactose properly because they ... of the potentially much more dangerous cow milk allergy, ... its own IgE antibodies. , According to statistics, about ... from a genuine milk allergy. Less adults are diagnosed ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
Breaking Medicine News(10 mins):Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3
... are warned of side effect that could hamper immigration ... widely used cancer drug capecitabine can cause people to ... they,re trying to enter the United States, an oncologist ... medical oncology at the National Cancer Centre in Singapore, ...
... learned at the Canadian-run military hospital in Kandahar, Afghanistan ... a London, Ontario physician who has served two tours ... professor in the Department of Surgery at the Schulich ... Western Ontario and a general surgeon at the London ...
... Recondo Technology, a leading provider of revenue ... today announced the firm,s selection as one ... Recondo as one of the top 100 companies ... http://www.newscom.com/cgi-bin/prnh/20090527/LA23009LOGO ) , (Logo: ...
... Johnson recognized by business leaders for vision, determination and ... Search America , a part of ... health care, today announced that its president, Daniel Johnson, ... & Young Entrepreneur of the Year(R) Award in Minnesota ...
... to develop new and more effective therapies to fight ... Team" of scientists and clinicians that is co-led by ... Department of Energy,s Lawrence Berkeley National Laboratory. , The ... Entertainment Industry Foundation charitable organization aimed at moving cancer ...
... Care Reform; Mark McClellan ModeratesWASHINGTON, May 27 ... to presenting comprehensive legislation to overhaul the nation,s ... Secretary Michael Leavitt and former Senate Majority Leader ... highlight the need for transparency and inclusion in ...
Cached Medicine News:Health News:Fingerprints May Vanish With Cancer Drug 2Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2Health News:Recondo Technology Wins Red Herring 100 North America Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 2Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 3Health News:NPC Newsmaker Program Hosts Briefing on Health Care Reform with Former HHS Secretary Michael Leavitt and Former Senate Majority Leader Tom Daschle 2
... are designed for the retraction of ... lesions. Reduced obstruction when working within ... range of blade sizes from 2 ... change and release, malleable material allows ...
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...
Telescopic Diamond-Dissectors for delicate sharp tissue preparation. Total/working lengths 220/240 mm with protective sleeve....
Epstein Curettes 3.0 mm, length 8" (203 mm)....
Medicine Products: